https://www.sec.gov/ix?doc=/Archives/edgar/data/1844840/000110465921115969/tm2127447d1_8k.htm
Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products
Kamada Ltd (NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics.